The ALEPH trial investigates ambrisentan monotherapy's efficacy and safety in early-stage, low-risk PAH to assess early therapeutic intervention benefits.
Does ambrisentan monotherapy improve efficacy and safety in patients with early-stage, low-risk pulmonary arterial hypertension?
The ALEPH trial aims to evaluate the efficacy and safety of ambrisentan monotherapy as an early therapeutic intervention for early-stage, low-risk pulmonary arterial hypertension.
Absolute Event Rate: 0% vs 0%
The ALEPH trial aims to generate high-quality evidence regarding the efficacy and safety of ambrisentan monotherapy in early-stage, low-risk PAH. This study may provide valuable insight into early therapeutic intervention for patients with mild hemodynamic disorder. (Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension ALEPH; NCT06987097).
Kan et al. (Sun,) reported a other. The ALEPH trial investigates ambrisentan monotherapy's efficacy and safety in early-stage, low-risk PAH to assess early therapeutic intervention benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: